Drug intelligence / Profile preview

DM934

Development stage: Unknown
Lead developer: Horus Pharma
Administration: Ophthalmic

Overview

DM934 is a topical ophthalmic product evaluated in clinical trials for the treatment of moderate to severe dry eye (ocular dryness). Its mechanism of action, precise ingredients, and molecular classification are not disclosed in available public sources. In a randomized, investigator-blinded study sponsored by Horus Pharma, DM934 is compared to Théalose for efficacy and safety in improving cornea and conjunctiva staining (Oxford score) and relieving dry eye symptoms in adult patients with ocular surface disease[2][4].

Brand names: DM934DM-934DM 934
Other names: DM934DM-934DM 934

Beyond the preview

Go deeper on DM934.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DM934.

Explore the full profile